Stefan Vielhaber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stefan Vielhaber has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Hans‐Jochen Heinze
Department of Neurology II, Otto‐von‐Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
3 shared publications- Wolfram S. Kunz
Department of Epileptology University Hospital Bonn, University of Bonn Bonn Germany
3 shared publications Grazyna Debska-Vielhaber
2 shared publicationsGrazyna Debska‐Vielhaber
Department of Neurology II, Otto‐von‐Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
2 shared publicationsHeiko G. Niessen
Department of Neurology II, Otto-von-Guericke University Magdeburg, Leipziger Str 44, Magdeburg, Germany
2 shared publications- Jerzy Duszyński
Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland
2 shared publications
Latest Publications
- 1 August 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1857, e107-e108
Mitochondrial stress response in fibroblasts derived from patients diagnosed with familial and sporadic form of ALS
- 1 August 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1857, e107-e108
Mitochondrial stress response in fibroblasts derived from patients diagnosed with familial and sporadic form of ALS
- 1 August 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1857, e77
A new answer to an old problem: The energization of brain mitochondria with pyruvate is regulated by cytosolic calcium via the mitochondrial gas pedal and does not require the mitochondrial Ca uptake via the Ca uniporter- New evidences from experiments with MCU -,- mice
- 1 August 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1857, e77
A new answer to an old problem: The energization of brain mitochondria with pyruvate is regulated by cytosolic calcium via the mitochondrial gas pedal and does not require the mitochondrial Ca uptake via the Ca uniporter- New evidences from experiments with MCU -,- mice
- 31 July 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1797, 77
Mitochondrial dysfunction in fibroblasts of patients with amyotrophic lateral sclerosis
- 31 July 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1797, 77
Mitochondrial dysfunction in fibroblasts of patients with amyotrophic lateral sclerosis
- 1 March 2007
- Published by Wiley in European Journal of Neuroscience
- Vol. 25 (6) , 1669-1677
Metabolic progression markers of neurodegeneration in the transgenic G93A‐SOD1 mouse model of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons. Visualizing corresponding metabolic changes in the brain of patients with ALS with proton magnetic resonance spectroscopy (1H‐MRS) may provide surrogate markers for an early disease detection, for monitoring the progression and for evaluating a treatment response. The primary objective of our study was to evaluate whether modifications in MR metabolite levels occur before clinical disease onset, and whether these changes are directly linked to a distinct spatial progression pattern in the CNS. Therefore, age‐dependent alterations in the cerebral and spinal metabolic profile in the mouse model of ALS overexpressing the mutated human G93A‐superoxide dismutase 1 (G93A‐SOD1) were determined by high‐resolution MRS of tissue extracts at 14.1 Tesla. Both non‐transgenic mice (control mice) and transgenic mice overexpressing the non‐mutated human SOD1 (tg‐SOD1) served as controls. In the spinal cord of G93A‐SOD1 mice significantly decreased levels of N‐acetyl aspartate were already detected 34 days postpartum, i.e. about 60 days before the average disease onset caused by motor neuron decline. In addition, glutamine and γ‐aminobutyric acid concentrations were significantly diminished at Day 75, which is still in the presymptomatic phase of the disease. These metabolic changes were further progressive in the course of the disease and started to involve the brainstem at Day 75. Overall, high‐resolution 1H‐MRS allows a sensitive spatial and temporal metabolite profiling in the presymptomatic phase of ALS even before significant neuronal cell loss occurs.
- 1 March 2007
- Published by Wiley in European Journal of Neuroscience
- Vol. 25 (6) , 1669-1677
Metabolic progression markers of neurodegeneration in the transgenic G93A‐SOD1 mouse model of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons. Visualizing corresponding metabolic changes in the brain of patients with ALS with proton magnetic resonance spectroscopy (1H‐MRS) may provide surrogate markers for an early disease detection, for monitoring the progression and for evaluating a treatment response. The primary objective of our study was to evaluate whether modifications in MR metabolite levels occur before clinical disease onset, and whether these changes are directly linked to a distinct spatial progression pattern in the CNS. Therefore, age‐dependent alterations in the cerebral and spinal metabolic profile in the mouse model of ALS overexpressing the mutated human G93A‐superoxide dismutase 1 (G93A‐SOD1) were determined by high‐resolution MRS of tissue extracts at 14.1 Tesla. Both non‐transgenic mice (control mice) and transgenic mice overexpressing the non‐mutated human SOD1 (tg‐SOD1) served as controls. In the spinal cord of G93A‐SOD1 mice significantly decreased levels of N‐acetyl aspartate were already detected 34 days postpartum, i.e. about 60 days before the average disease onset caused by motor neuron decline. In addition, glutamine and γ‐aminobutyric acid concentrations were significantly diminished at Day 75, which is still in the presymptomatic phase of the disease. These metabolic changes were further progressive in the course of the disease and started to involve the brainstem at Day 75. Overall, high‐resolution 1H‐MRS allows a sensitive spatial and temporal metabolite profiling in the presymptomatic phase of ALS even before significant neuronal cell loss occurs.
- 26 April 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (2) , 145-152
Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1
To evaluate cerebral metabolism and intergroup differences in closely matched patients with myotonic dystrophy type 2 (DM2, n = 15) and type 1 (DM1, n = 14), we performed 1H magnetic resonance spectroscopic (MRS) analyses of the occipital and temporoparietal cortical regions as well as of subcortical frontal white matter. Relative to healthy subjects, the concentration of N‐acetylaspartate was significantly reduced in all tested brain regions in both disease groups. In the DM1 patients we also observed a concomitant depletion of creatine and choline levels, particularly in the frontal white matter. A discriminant analysis based on the 1H‐MRS data distinguished between the DM2, DM1, and control groups with an overall accuracy of 88%. 1H‐MRS indicates that neurochemical alterations involving gray and white matter occur in patients with DM2 and DM1. Although structural abnormalities (cerebral atrophy, white matter lesions) are similar in DM2 and DM1, changes in cerebral metabolites can differentiate these disease groups, suggesting that the diseases differ in their neurocellular pathology. Muscle Nerve, 2006
- 26 April 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (2) , 145-152
Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1
To evaluate cerebral metabolism and intergroup differences in closely matched patients with myotonic dystrophy type 2 (DM2, n = 15) and type 1 (DM1, n = 14), we performed 1H magnetic resonance spectroscopic (MRS) analyses of the occipital and temporoparietal cortical regions as well as of subcortical frontal white matter. Relative to healthy subjects, the concentration of N‐acetylaspartate was significantly reduced in all tested brain regions in both disease groups. In the DM1 patients we also observed a concomitant depletion of creatine and choline levels, particularly in the frontal white matter. A discriminant analysis based on the 1H‐MRS data distinguished between the DM2, DM1, and control groups with an overall accuracy of 88%. 1H‐MRS indicates that neurochemical alterations involving gray and white matter occur in patients with DM2 and DM1. Although structural abnormalities (cerebral atrophy, white matter lesions) are similar in DM2 and DM1, changes in cerebral metabolites can differentiate these disease groups, suggesting that the diseases differ in their neurocellular pathology. Muscle Nerve, 2006
- 25 March 2002
- Published by Wiley in Muscle & Nerve
- Vol. 25 (4) , 540-548
Facioscapulohumeral muscular dystrophy with EcoRI/BlnI fragment size of more than 32 kb
Facioscapulohumeral muscular dystrophy (FSHD) is associated with the deletion of a variable number of 3.3‐kb subunits of a tandemly arranged repeat (D4Z4) on chromosome 4q35. EcoRI/BlnI fragments in the range of 10–35 kb are currently defined as disease‐associated. Diagnosis of FSHD is frequently complicated by interchromosomal exchange with a homologous locus on 10q26. We present clinical and laboratory data of six subjects from two unrelated families with a marked FSHD phenotype and EcoRI/BlnI fragments of 39 and 33 kb, respectively. Origin on chromosome 4q35 was confirmed by haplotype analysis in the first family and was supported by pulsed field gel electrophoresis data in the second family. Our data further confirm the existence of a region of overlap of normal and pathological fragments. Fragments from this region can obviously be associated with marked FSHD phenotypes. Furthermore, application of linked markers and resolution of all EcoRI/BlnI fragments by pulsed field gel electrophoresis in addition to routine laboratory tests considerably augments the information obtained from molecular tests, upon which genetic counselling can then be based. © 2002 Wiley Periodicals, Inc. Muscle Nerve 25: 000–000, 2002
- 25 March 2002
- Published by Wiley in Muscle & Nerve
- Vol. 25 (4) , 540-548
Facioscapulohumeral muscular dystrophy with EcoRI/BlnI fragment size of more than 32 kb
Facioscapulohumeral muscular dystrophy (FSHD) is associated with the deletion of a variable number of 3.3‐kb subunits of a tandemly arranged repeat (D4Z4) on chromosome 4q35. EcoRI/BlnI fragments in the range of 10–35 kb are currently defined as disease‐associated. Diagnosis of FSHD is frequently complicated by interchromosomal exchange with a homologous locus on 10q26. We present clinical and laboratory data of six subjects from two unrelated families with a marked FSHD phenotype and EcoRI/BlnI fragments of 39 and 33 kb, respectively. Origin on chromosome 4q35 was confirmed by haplotype analysis in the first family and was supported by pulsed field gel electrophoresis data in the second family. Our data further confirm the existence of a region of overlap of normal and pathological fragments. Fragments from this region can obviously be associated with marked FSHD phenotypes. Furthermore, application of linked markers and resolution of all EcoRI/BlnI fragments by pulsed field gel electrophoresis in addition to routine laboratory tests considerably augments the information obtained from molecular tests, upon which genetic counselling can then be based. © 2002 Wiley Periodicals, Inc. Muscle Nerve 25: 000–000, 2002